| |
|
News |
2007 | 2006 | 2005 | Archived |
2004 |
|
November 4, 2004 |
Gemin X Biotechnologies Initiates Phase 1 Clinical Trial with Novel Cancer Drug Candidate GX15-070 |
February 19, 2004 |
Gemin X Biotechnologies to Webcast Presentation at BIO CEO & Investor Conference |
2003 |
|
December 10, 2003 |
Gemin X Biotechnologies Appoints Andrew R. Jordan to its Board of Directors |
September 17, 2003 |
Gemin X Biotechnologies to Present at UBS Global Life Sciences Conference |
February 20, 2003 |
Gemin X Hires Jean Viallet, M.D., Former Group Director of Clinical Development and Medical Affairs at GlaxoSmithKline, as VP of Clinical Development |
2002 |
|
November 22, 2002 |
Gemin X Reports In-Vivo and In-Vitro Efficacy of Small Molecule Apoptosis-Inducers for the Treatment of Cancer |
July 1, 2002 |
Gemin X Biotechnologies and Sequoia Sciences Announce Drug Discovery Collaboration |
February 13, 2002 |
Tranzyme and Gemin X Announce Joint Drug Discovery Partnership |
2001 |
|
December 4, 2001 |
Gemin X Appoints Giorgio Attardo, Ph.D., Director of Medicinal Chemistry |
October 31, 2001 |
Gemin X Demonstrates In Vivo Efficacy of Proprietary Cancer Specific Apoptosis Inducers |
October 31, 2001 |
Gemin X Reports In Vivo Efficacy of Viral Death Protein in Cancer |
September 25, 2001 |
Gemin X Co-Founder, Philip Branton, Ph.D., Appointed Scientific Director of the Institute of Cancer Research |
August 24, 2001 |
Gemin X Awarded $350,000 Contribution From the National Research Council of Canada |
June 20, 2001 |
Gemin X Appoints Sanderling's Robert McNeil, Ph.D. as Chairman |
May 15, 2001 |
Phytera and Gemin X Sign Cancer Drug Discovery Collaboration |
May 3, 2001 |
Gemin X Secures U.S. $12.6 Million in Second Round Funding |
2000 |
|
No press releases during the year 2000 |
1999 |
|
October 6, 1999 |
Gemin X Presents Discovery of Novel Bcl-2 Inhibitor as Anticancer Agent at Conference on Differentiation Therapy |
return to top
|
|
